Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider by Alunno, A et al.
  1Alunno A, et al. Ann Rheum Dis 2021;0:1–13. doi:10.1136/annrheumdis-2020-219725
Miscellaneous
CLINICAL SCIENCE
Immunomodulatory therapies for SARS- CoV-2 
infection: a systematic literature review to inform 
EULAR points to consider
Alessia Alunno   ,1 Aurélie Najm   ,2 Xavier Mariette,3 Gabriele De Marco,4,5 
Jenny Emmel,6 Laura Mason,6 Dennis G McGonagle,4,5 Pedro M Machado   7,8,9
To cite: Alunno A, 
Najm A, Mariette X, et al. 
Ann Rheum Dis Epub ahead 
of print: [please include Day 
Month Year]. doi:10.1136/
annrheumdis-2020-219725
Handling editor Désirée van 
der Heijde
For numbered affiliations see 
end of article.
Correspondence to
Dr Alessia Alunno, 
Rheumatology Unit, Department 
of Medicine, University of 
Perugia, 06123 Perugia, Umbria, 
Italy;  
 alessia. alunno82@ gmail. com
AA and AN contributed equally.
Received 15 December 2020
Revised 24 January 2021
Accepted 27 January 2021
 ► http:// dx. doi. org/ 10. 1136/ 
annrheumdis- 2020- 219724
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published 
by BMJ.
ABSTRACT
Objective To summarise the available information 
on efficacy and safety of immunomodulatory agents in 
SARS- CoV-2 infection.
Methods As part of a European League Against 
Rheumatism (EULAR) taskforce, a systematic literature 
search was conducted from January 2019 to 11 
December 2020. Two reviewers independently identified 
eligible studies according to the Population, Intervention, 
Comparator and Outcome framework and extracted data 
on efficacy and safety of immunomodulatory agents used 
therapeutically in SARS- CoV-2 infection at any stage. The 
risk of bias was assessed with validated tools.
Results Of the 60 372 records, 401 articles were 
eligible for inclusion. Studies were at variable risk of 
bias. Randomised controlled trials (RCTs) were available 
for the following drugs: hydroxychloroquine (n=12), 
glucocorticoids (n=6), tocilizumab (n=4), convalescent 
plasma (n=4), interferon beta (n=2), intravenous 
immunoglobulins (IVIg) (n=2) and n=1 each for 
anakinra, baricitinib, colchicine, leflunomide, ruxolitinib, 
interferon kappa and vilobelimab. Glucocorticoids were 
able to reduce mortality in specific subsets of patients, 
while conflicting data were available about tocilizumab. 
Hydroxychloroquine was not beneficial at any disease 
stage, one RCT with anakinra was negative, one RCT 
with baricitinib+remdesivir was positive, and individual 
trials on some other compounds provided interesting, 
although preliminary, results.
Conclusion Although there is emerging evidence 
about immunomodulatory therapies for the management 
of COVID-19, conclusive data are scarce with some 
conflicting data. Since glucocorticoids seem to 
improve survival in some subsets of patients, RCTs 
comparing glucocorticoids alone versus glucocorticoids 
plus anticytokine/immunomodulatory treatment are 
warranted. This systematic literature review informed 
the initiative to formulate EULAR ’points to consider’ 
on COVID-19 pathophysiology and immunomodulatory 
treatment from the rheumatology perspective.
INTRODUCTION
SARS- CoV-2 infection encompasses a heteroge-
neous clinical picture ranging from asymptomatic 
to multisystem life- threatening manifestations. 
Although the majority of patients experience only 
mild to moderate symptoms, a relevant proportion 
of infected subjects may develop respiratory failure, 
acute respiratory distress syndrome and death.1 2 
The severest forms of COVID-19 pneumonia are 
associated with severe pulmonary inflammatory 
responses, including oedema and inflammatory 
cell infiltration with severe alveolitis and associ-
ated pulmonary immunothrombosis. Beside the 
Key messages
What is already known about this subject?
 ► The SARS- CoV-2 pandemic is a global health 
problem. Aberrant host immune response plays 
an important role throughout the course of 
mild, moderate and severe COVID-19.
 ► There is intense investigation to explore the 
utility of immunomodulatory drugs commonly 
used in the rheumatology arena as agents that 
may mitigate against COVID-19 to improve 
disease prognosis.
What does this study add?
 ► Robust and reliable evidence of the efficacy 
of immunomodulatory therapies is scarce, but 
results from randomised controlled trials (RCTs) 
ruled out any benefit of hydroxychloroquine 
at any stage of SARS- CoV-2 infection 
while demonstrating the ability of some 
glucocorticoids to reduce mortality in specific 
patient subsets with severe COVID-19.
 ► Data from RCTs on tocilizumab are conflicting, 
and definite conclusions cannot be drawn 
at this point in time. Anakinra was not 
effective in the only available RCT, while 
baricitinib+remdesevir was effective in specific 
patient subgroups (patients with non- invasive 
ventilation) in the only available RCT.
 ► Evidence for several immunomodulatory 
compounds is scarce, and data from RCTs are 
required to elucidate their role in the context of 
different phenotypes of SARS- CoV-2 infection.
How might this impact on clinical practice or 
future developments?
 ► This systematic literature review evaluated the 
evidence pertaining to immunomodulatory 
drugs where there is some evidence for efficacy 
in severe COVID-19 and a good safety profile 
thus far.
 ► Further evidence is needed regarding the 
optimal use and consideration of combination 
therapies for severe disease in a rapidly 
evolving arena.
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specific pathogenic effect of SARS- CoV-2, the immune response 
may be deleterious and excessive since postmortem studies may 
show excessive immune activation but a paucity of evidence for 
active viral alveolitis. A vicious circle encompassing the intrapul-
monary release of proinflammatory mediators, along with the 
aberrant activation of immune cells, coagulopathy and histo-
logical evidence of haemophagocytosis in patients with more 
severe COVID-19 demonstrated some features that resembled 
the macrophage activation syndrome (MAS) also known as 
secondary haemophagocytic lymphohistocytosis (sHLH).3 4
Rheumatologists routinely use immunomodulatory drugs 
and are well aware of conditions like MAS/sHLH that may be 
observed as a complication of autoimmune or inflammatory 
rheumatic and musculoskeletal diseases (RMDs). On this basis, 
a large number of immunomodulatory drugs used in rheuma-
tology for years have been investigated in SARS- CoV-2 infection, 
particularly severe COVID-19. This systematic literature review 
(SLR) was performed to inform the EULAR taskforce respon-
sible for developing the points to consider (PtC) on COVID-19 
pathophysiology and immunomodulatory treatment as viewed 
from the rheumatology perspective. Specifically, the SLR aimed 
to summarise the available information on the use of immuno-




The EULAR task force that developed PtCs on COVID-19 patho-
physiology and immunomodulatory treatment from the rheuma-
tology perspective outlined the scope of the systematic literature 
search, according to the Population, Intervention, Comparator 
and Outcome approach.5 Based on a set of research questions 
encompassing the pathogenesis of SARS- CoV-2 infection, its 
management with immunomodulatory agents and its possible 
role as trigger of new- onset RMDs, three separate searches 
(online supplemental text S1−S4) were performed. The searches 
were performed in MEDLINE, Embase, The Cochrane Database 
of Systematic Reviews, CENTRAL and CINAHL. The searches 
on pathogenesis and RMDs were conducted up to 2 November 
2020, while the one on immunomodulatory treatment up to 
11 December 2020. The PubMed Similar Articles tool was also 
used, and a crosscheck of the key scientific journals in general 
medicine and immunology was performed. Non peer- reviewed 
literature was excluded given this SLR aimed at informing recom-
mendations. However, given the rapid evolution of knowledge 
on COVID-19 treatment, a parallel hand search of ‘grey litera-
ture’ consisting only of RCT not yet published in peer- review 
journals but accessible in press releases or in extenso in preprint 
repositories was performed. These not yet published RCTs are 
presented separately and were not used to inform the PtC. In 
order to ensure this SLR to be as comprehensive as possible and 
provide an overview of all evidence (regardless of the level), no 
restriction to specific study design (eg, randomised controlled 
trials (RCTs)) was defined. The results of the search focused 
on the pathogenesis of SARS- CoV-2 infection are published 
elsewhere.
Study selection, data collection and assessment of risk of bias 
(RoB)
Briefly, original research articles of any study design, published 
in English, in peer- reviewed journals and addressing adults with 
proven SARS- CoV-2 infection treated with one or more immu-
nomodulatory agent were eligible (online supplemental text 
S4). Two reviewers (AA and AN) independently assessed titles 
and abstracts according to the predetermined eligibility criteria, 
followed by full- text review. The agreement between reviewers, 
calculated with the Cohen’s kappa, was 0.95. Discrepancies were 
resolved by discussion. The task force methodologist (PMM) was 
consulted in the case of uncertainties. Data on patient character-
istics, investigated drug administration scheme and comparators 
and outcomes were extracted. The RoB was assessed using vali-
dated tools according to the study design (online supplemental 
text S5). Only the results pertaining to immunomodulatory ther-
apies are presented here.
RESULTS
Of the 60 372 records yielded by the three searches, 700 were 
selected for full- text review and seven additional articles were 
identified by cross- referencing. Of these, 401 articles on 33 ther-
apeutic strategies met the inclusion criteria for the research ques-
tions on immunomodulatory treatment of COVID-19 (online 
supplemental tables S1−S3). Robust evidence was mostly 
available for moderate to severe/critical COVID-19. The best 
evidence available for each compound is shown.
Immunomodulatory therapies with evidence on severe 
(patients on oxygen therapy) or critical (patients in intensive 
care unit (ICU)) COVID-19
Data from RCTs
A total of 39 RCTs, all at high or unclear RoB, evaluating 13 ther-
apeutic approaches in severe/critical COVID-19 were retrieved 
by the SLR (online supplemental table S4).
Glucocorticoids
Efficacy
Of the six RCTs on glucocorticoids in severe/critical COVID-
19, two investigated dexamethasone (DEX) (one at unclear 
and one at high RoB), two investigated methylprednisolone 
(MTP) (one at unclear and one at high RoB) and two investi-
gated hydrocortisone (HCT) (both at unclear RoB). Most of 
the studies included severe and critical patients with between 
15% and 100% of subjects requiring invasive mechanical 
ventilation (IMV).6–11 In one study at high RoB, none of the 
patients needed IMV at enrolment.11 This, along with the 
variability of other inclusion criteria, the use of different 
compounds (eg, long acting vs short acting) and different 
schedule may have contributed to the conflicting results for 
the majority of outcomes in the overall analysis (tables 1 and 
2). Conversely, subgroup analyses revealed positive results 
for two (DEX and MTP) out of three compounds with regard 
to mortality (figure 1). The study from the RECOVERY 
Collaborative Group (unclear RoB) enrolled 6425 patients 
with severe COVID-19 of which 2104 were assigned to 
receive DEX in addition to standard of care (SOC) and 4321 
to receive SOC only.6 The two groups were comparable 
with regard to need of oxygen therapy/non- invasive or IMV 
at randomisation. The addition of DEX to SOC reduced 
mortality but only in patients requiring respiratory support. 
Likewise, the addition of MTP to SOC in a study at unclear 
RoB was able to reduce mortality in patients aged 60 years 
or over.7 HCT failed to show benefit in reducing mortality 
in both studies.9 10 Importantly, the RECOVERY trial also 
reported that in patients not receiving oxygen therapy, DEX 
may have a possible (even if not statistically significant) dele-
terious effect on mortality (OR=1.22, 95% CI 0.93 to 1.61, 
p=0.14).6
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The two studies on DEX yielded conflicting results with 
regard to the need of IMV; however, a lack of stratification 
of inpatients with mild to moderate pneumonia receiving 
oxygen therapy did not allow us to untangle the effect of 
DEX in patients requiring a low rate of oxygen (1–2 L/min) 
from the effect in those requiring higher rate (3–15 L/min). 
In addition, the studies on MTP and HCT assessing the need 
of IMV7 10 found no beneficial effect of these compounds. 
One additional study on HCT in patients with COVID-19 
requiring oxygen therapy ≥10 L/min (COVID-19 STEROID) 
emerged from the search of the ‘grey literature’, reporting 
no benefit of HCT on 28- day all- cause mortality.12
Safety
Only one study identified safety concerns related to glucocorti-
coids use in severe COVID-19 with a reported increased insulin 
use at day 7 in patients treated with MTP+SOC compared with 
SOC.7 The other RCTs reported either no difference between 
groups8 or descriptive information without statistical assessment 
of differences (table 3).9–11
Hydroxychloroquine
Efficacy
Of the nine RCTs on hydroxychloroquine (HCQ) in severe COVID-
19, three studies at high RoB did not report any information 
regarding the proportions of patients requiring oxygen therapy/
NIMV/IMV,13–15 two studies reported NIMV/IMV as exclusion 
criterion16 17 and four studies detailed the proportion of enrolled 
patients received either oxygen therapy, NIMV or IMV.18–21 The 
studies assessing mortality,13 16 18–20 three at unclear and one at high 
RoB, agreed that the addition of HCQ to SOC did not provide 
any beneficial effect. As far as clinical severity is concerned, HCQ 
did not reduce the need of IMV,13 16 19 but one RCT at unclear 
RoB demonstrated a higher risk of progression to IMV in patients 
treated with HCQ+SOC compared with SOC only18 (tables 1 and 
2). From the parallel hand search in the ‘grey literature’, we iden-
tified one additional RCT on HCQ that was prematurely discon-
tinued due to inefficacy—the ORCHID trial.22
Safety
Two studies at unclear RoB alerted on safety issues regarding 
HCQ. Overall, more adverse events occurred in the HCQ- 
treated groups. One study reported higher frequency of QTc 
prolongation and elevation in liver enzyme levels in HCQ- treated 
patients.16 The other study reported a greater risk of death in 
HCQ- treated patients, either from non- SARS- CoV-2 infections 
or from cardiac causes, although the incidence of arrhythmias 
was similar across groups.18 It is important to mention that the 
schedule of HCQ in the above- mentioned RCTs was higher 
than that used in rheumatology practice (eg, a stable dose of 
800 mg/day or 800 mg/day for a few days followed by 400 mg/
day). Furthermore, the combination with other drugs that could 
prolongate the QT interval such as azithromycin may account 
for the safety concerns.
Tocilizumab
Efficacy
Three RCTs on tocilizumab (TCZ) at unclear RoB were 
retrieved.23–25 In all studies, NIV/IMV represented an exclu-
sion criterion; however, only the CORIMUNO-19 trial 
excluded also hospitalised patients without need of oxygen 
therapy, focusing only on patients requiring at least 3 L/min 
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day 28 in the former two RCTs was rather low (2%–5%), 
suggesting that they may have enrolled milder patients than 
CORIMUNO-19. In Stone’s study, 16% of patients did not 
receive oxygen therapy. While Stone et al24 and Salvarani 
et al25 failed to demonstrate any benefit from the addition 
of TCZ to SOC for all the outcomes assessed, the CORI-
MUNO-19 trial demonstrated benefit of adding TCZ to 
SOC with regard to lower progression to NIV, IMV or death, 
although day-28 mortality did not differ between groups.
Two additional RCTs on TCZ were identified in the ‘grey 
literature’. The EMPACTA trial, using the same inclusion 
criteria as CORIMUNO-19, met the composite primary 
outcome of death or IMV at day 28 and was published in The 
New England Journal of Medicine on 17 December 2020.26 
Conversely, the COVACTA trial did not show a benefit in 
terms of clinical improvement or mortality in the overall 
population. Unlike the above- mentioned studies, NIV/IMV 
were not an exclusion criteria in COVACTA, and of note, 
65%–70% of patients were receiving either of the two.27 
However, positive results were reported in a post hoc analysis 
with a significantly lower proportion of patients experiencing 
clinical failure in the subgroup not receiving IMV at randomi-
sation (table 4). In patients recently admitted to ICU within 1 
day, the REMAP- CAP study was prematurely stopped because 
of positive results on hospital mortality with TCZ (28% for 
TCZ vs 35.8% for controls) and on day 90 survival with TCZ: 
(median HR=1.59 (1.24 to 2.05), probability of superiority of 
TCZ >99.9%) (table 4).28 Lastly, an RCT reporting that TCZ 
was not superior to SOC in improving clinical outcomes at 15 
days was published on 22 January 2021.29
Safety
The safety profile of TCZ was good, with the study by Stone et 
al24 showing fewer serious infections in the TCZ group in spite 
of an increase rate of neutropaenia.
Table 2 Effect of immunomodulatory drugs on invasive and non- invasive ventilation and on oxygen support, assessed by randomised controlled 
trials, in moderate to severe COVID-19 (with oxygen therapy) and in critical COVID-19 (patients in ICU)





Hydroxychloroquine Cavalcanti et al 202016 SOC+PBO
SOC+HCQ + AZT
No difference between groups HCQ OR 1.77 (95% CI 0.81 to 3.87) HCQ+AZT 
OR 1.15 (95% CI 0.49 to 2.70).
Unclear




No difference between groups (4.1% vs 5.2%, p=0.75). High
    RECOVERY 202018 SOC
SOC+HCQ
Higher progression to IMV in the HCQ group (risk ratio (RR) 1.14; 95% CI 1.03 
to 1.27).
Unclear
  Corticosteroids RECOVERY 20206 SOC+DEX
SOC
Risk of progression to IMV was lower in the DEX group than in SOC group (RR 
0.77; 95% CI 0.62 to 0.95).
Unclear
    Jeronimo et al 20207 SOC+MTP
SOC
No difference across groups day 7 hour 2.6 (95% CI 8.6 to 13.6); p=0.654. Unclear
    Tomazini et al 20208 SOC+DEX
SOC
6.6 (95% CI 5.0 to 8.2) in the DEX group versus 4.0 ventilator- free days (95% 
CI 2.9 to 5.4) in the SOC group (difference: 2.26; 95% CI 0.2 4.38; p=0.04).
High
    Dequin et al 202010 SOC+HCT
SOC+PBO
Of the 16 patients per group without IMV at baseline, 8 (50%) in HCT group 
and 12 (75%) in the PBO group required subsequent intubation.
Unclear




At day 14, 12% (95% CI 28% to 4%) fewer patients needed NIV or MV or died 
in the TCZ group than in the SOC group (24% vs 36%, median posterior HR 
0.58; 90% credible interval 0.33 to 1.00).
Unclear
    Stone et al24 SOC+TCZ
SOC+PBO
No difference across groups in the progression to IMV or death. 0.83 (95% CI 
0.38 to 1.81; p=0.64).
Unclear




No difference across groups. The proportion of patients dead or in need of NIV 
or IMV on day 14. (47%, vs 51%, HR 1.0 (0.6–1.5).
Unclear
  Ruxolitinib (RUXO) Cao et al 202036 SOC+RUXO SOC 
+100 mg vitamin C
No difference between groups in the need of NIV or IMV and if needed in the 
duration (p=0.633 and p=0.232).
High
  Interferon (IFN) beta Davoudi- Monfared et 
al 2020, Rahmani et al 
202033 34
SOC+IFN beta SOC No difference between groups in the need of MV and if needed in the 
duration.
High
    Monk et al 202035 SOC+IFN beta PBO 
+SOC
No significant difference between treatment groups in the odds of intubation 
or the time to intubation.
Unclear
  IVIg Tabarsi et al 202040 SOC+IVIg SOC No difference in need for IMV (p=0.39) (n=21 IVIG vs n=10 control group). High
  Baricitinib Kalil et al 202031 BARI+RDV+ SOC. 
PBO+RDV+SOC
The incidence of progression to death or NIV or MIV was lower in the 
RDV+BARI (22.5% vs 28.4%; rate ratio: 0.77; 95% CI 0.60 to 0.98), as was 
the incidence of progression to death or MIV (12.2% vs 17.2%; rate ratio 0.69; 
95% CI 0.50 to 0.95).
Unclear
Oxygen support Hydroxychloroquine Cavalcanti et al 202016 SOC+PBO
SOC+HCQ + AZT
No difference between groups
HCQ+AZT OR 1.10 (95% CI 0.60 to 2.03) HCQ OR 1.19 (95% CI 0.65 to 2.21).
Unclear
  Tocilizumab Stone et al 202024 SOC+TCZ
SOC+PBO
The median time to discontinuation of supplemental O2 was 5.0 days (95% CI 
3.8 to 7.6) in the TCZ group and 4.9 days (95% CI 3.8 to 7.8) in the placebo 
group (p=0.69). No difference across groups.
Unclear
  Interferon beta 1a Davoudi- Monfared et 
al 2020, Rahmani et al 
202033 34
IFN beta+SOC SOC No difference between groups. High
Only studies reporting on the corresponding outcomes are shown.
AZT, azithromycin; BARI, baricitinib; DEX, dexamethasone; HCQ, hydroxychloroquine; HCT, hydrocortisone; ICU, intensive care unit; IFN, interferon; IMV, invasive mechanical ventilation; MTP, 
methylprednisolone; NIV, non- invasive ventilation; PBO, placebo; RDV, remdesivir; RR, relative risk; RUXO, ruxolitinib; SOC, standard of care; TCZ, tocilizumab.
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One RCT assessed anakinra in patients with COVID-19 
requiring at least 3 L/min oxygen therapy (CORIMUNO-19) 
and was published online in The Lancet Respiratory Medicine on 
22 January 2021.30 The addition of the drug to SOC failed to 
improve survival without NIV (including high- flow oxygen) or 
IMV at day 14 or survival at day 90.
Safety
From a safety perspective, there was a numerical increase of 
serious infections in the anakinra group.
Baricitinib
Efficacy
At present, the only RCT available on baricitinib in SARS- CoV-2 
infection compared remdesevir+baricitinib versus remdese-
vir+placebo.31 Patients receiving remdesevir+baricitinib had a 
median time to recovery of 7 days, as compared with 8 days 
in the remdesevir+placebo group (rate ratio for recovery: 1.16; 
95% CI 1.01 to 1.32; p=0.03), which is statistically significant 
but clinically probably not meaningful, except in the subgroup 
of patients with a baseline NIV (including high flow oxygen) in 
whom median time to recovery was 10 days with the combina-
tion therapy, as compared with 18 days in the remdesivir only 
control group (rate ratio for recovery: 1.51; 95% CI 1.10 to 
2.08). It is important to note that the global mortality in the 
ACTT-2 trial was lower (around 5%) than in other trials like 
the RECOVERY DEX trial (around 20%) that might explain 
the modest effect size observed in ACTT-2. Interestingly, the 
ACTT-4, evaluating the combination of baricitinib and remde-
sivir compared with DEX and remdesivir is currently ongoing.32
Safety




The SLR yielded three publications on two RCTs on inter-
feron (IFN) beta,33–35 one on the Janus kinase inhibitor 
ruxolitinib,36 one on anti- C5a vilobelimab,37 one on colchi-
cine,38 two on IVIg39 40 and three on convalescent plasma.41–43 
The studies on vilobelimab and colchicine were at unclear 
RoB, while all the others were at high RoB. The studies on 
IFN- beta provided conflicting results on mortality and other 
clinical outcomes (tables 2 and 3).33–35 No differences on 
mortality or in the need of IMV were observed in patients 
treated with ruxolitinib,36 while IVIg reduced mortality in 
hospitalised patients requiring NIMV/IMV.39 The addition 
of colchicine to SOC allowed a larger number of patients 
to achieve cumulative event- free 10- day survival, using a 
composite outcome including mortality or need of IMV, 
and a lower number of patients displayed clinical deteriora-
tion.38 However, patients with a slightly milder phenotype 
not requiring IMV were enrolled. On 24 January 2021 the 
results of the large COLCORONA trial have been released 
highlighting that colchicine reduced hospitalisation, use 
Figure 1 Forest plots showing the risk ratio (RR) and 95% CI for mortality in randomised controlled trials divided by intervention. The latest follow- 
up available is reported in the timing column. Panel A shows RRs in overall cohorts, panel B shows overall cohorts and subgroup analysis in studies 
assessing glucocorticoids and panel C shows all studies on tocilizumab (including grey literature).
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of ventilation and mortality.44 Vilobelimab was not effec-
tive on any of the outcomes assessed (table 4). All studies 
on convalescent plasma failed to show any efficacy on 
28- day mortality, progression to severe disease42 or clinical 
improvement at 2841 or 3043 days. On the day of submission 
of this article, a press release announced that the phase III 
RUXCOVID study evaluating ruxolitinib+SOC compared 
with placebo+SOC in patients with COVID-19 did not meet 
its primary endpoint of reducing the number of hospitalised 
patients with COVID-19 who experienced severe complica-
tions (death, mechanical ventilation or ICU care).45 Finally, 
a press release on 2 July 2020 reported the failure of a phase 
III trial assessing sarilumab in critical patients (requiring 
IMV) with COVID-19,46 while in the above- mentioned 
REMAP- CAP study (grey literature) assessing TCZ and 
sarilumab demonstrated efficacy of the latter in improving 
survival and other outcomes.28
Safety
Ruxolitininb and vilobelimab and convalescent plasma 
showed a good safety profile. Conversely, data were 
conflicting for IFN- beta, not reported for IVIg and worse 
safety profile for colchicine since authors highlighted 
a higher frequency of diarrhoea in colchicine- treated 
patients.
Data from prospective or retrospective controlled studies
Prospective controlled studies were identified as best avail-
able evidence for eight therapeutic strategies, three of which 
Table 3 Safety of immunomodulatory drugs assessed by randomised controlled trials in moderate- to- severe COVID-19 (with oxygen therapy) and 
in critical COVID-19 (patients in ICU)
Drug Author, year Study groups Results RoB
Hydroxychloroquine Cavalcanti et al 202016 SOC+PBO
SOC+HCQ+AZT
Prolongation of the corrected QT interval (p=0.04 for HCQ+AZT; p=0.01 for HCQ) 
and elevation of liver enzyme p=0.02.
More SAE and two deaths in HCQ+AZT groups.
Unclear
  RECOVERY 202018 SOC
SOC+HCQ
HCQ group: greater risk of death from cardiac causes (mean (±SE) excess, 0.4±0.2 
percentage points) and from non–SARS- CoV-2 infection (mean excess, 0.4±0.2 
percentage points).
Unclear
  Tang et al 202015 SOC
SOC+HCQ
21 (30%) patients HCQ vs 7 (9%) patients PBO. High
  Huang et al 202014 SOC+HCQ
SOC
5 patients, 9 AEs in HCQ group, none in control group. High
  Self et al 202020 SOC+HCQ
SOC
30 SAEs were reported, including 18 SAEs from 14 patients (5.8%) in the HCQ 
group and 12 serious adverse events from 11 patients (4.6%) in the control group.
Unclear
  Ulrich et al 202021 SOC+HCQ
SOC
No difference in AEs between the groups. HCQ was associated with a slight 
increase in mean corrected QT interval, an increased D- dimer, and a trend towards 
an increased length of stay.
High
Corticosteroids Jeronimo et al 20207 SOC+MTP
SOC+PBO
More insulin at day 7 needed in the MTP group.
No more sepsis (but antibiotics in the SOC regimen).
Unclear
  Tomazini et al 20208 SOC+DEX
SOC
No difference in AEs between groups. High
  Dequin et al 202010 SOC+HCT
SOC+PBO
The proportions of bacteraemia were 6.6% in the hydrocortisone group and 11.0% 
in the placebo group.
Unclear
  Edalatifard et al 202011 SOC+MTP
SOC
2 patients in each group (5.8% and 7.1%) showed SAE. High
  Angus et al 20209 SOC+HCT
SOC
10 patients (2.6%) with SAE, 9 of whom were in the fixed- dose (n=4) and shock- 
dependent (n=5) HCT groups. Two events (severe neuromyopathy and fungaemia) 
occurred in the fixed- dose hydrocortisone group.
Unclear
Convalescent plasma Simonovich et al 202043 SOC+convalescent plasma
SOC+PBO
No difference in AEs between groups. Unclear
  Li et al 202041 SOC+convalescent plasma SOC No difference in AEs between groups. High
  Agarwal et al 202042 SOC+convalescent plasma. SOC No difference in AEs between groups. High
Tocilizumab Stone et al 202024 SOC+TCZ
SOC+PBO
Neutropaenia developed in 22 patients in the TCZ group, as compared with only 
one patient in the placebo group (p=0.002), but serious infections occurred in 
fewer patients in the TCZ group (13 (8.1%) vs 14 (17.3%); p=0.03).
Unclear




SAE occurred in 20 (32%) patients in the TCZ group and 29 (43%) in the SOC group 
(p = 0.21). Serious infections occurred in 2 (3%) patients in the TCZ group and 14 
(21%) in the control group. Neutropaenia developed in 4 (6%) in the TCZ group 
and 0 in the control group.
Unclear
Colchicine Deftereos et al 202038 SOC+COL
SOC
Diarrhoea was more frequent in the colchicine group (25 patients(45.5%) versus 
nine patients (18.0%); p = 0.003).
Unclear
Ruxolitinib Cao et al 202036 SOC+RUXO
SOC
No differences between groups 15 patients (71.4%) PBO group and 16 (80%) in 
RUXO group.
High
Interferon beta Davoudi- Monfared et al 2020, 
Rahmani et al 202033 34
SOC+IFN beta SOC No differences between groups (all p>0.05). A total of 47 common AEs in the IFN 
and 62 in the control group.
High
  Monk et al 202035 SOC+IFN beta PBO+SOC Treatment emergent AEs were more common in the IFN group. Unclear
Vilobelimab Vlaar et al37 SOC+VIL SOC Numbers of SAE were similar between groups (60% of patients in the IFX-1 group 
vs 47% in the control group).
Unclear
Baricitinib Kalil et al 202031 BARI+RDV+ SOC 
PBO+RDV+SOC
No difference in AEs between groups. Unclear
Only studies reporting on safety are shown.
AE, adverse event; AZT, azithromycin; COL, colchicine; DEX, dexamethasone; HCQ, hydroxychloroquine; HCT, hydrocortisone; IFN, interferon; MTP, methylprednisolone; MV, mechanical ventilation; PBO, placebo; RR, 
relative risk; RUXO, ruxolitinib; SAE, severe adverse event; SE, standard error; SOC, standard of care; TCZ, tocilizumab; VIL, vilobelimab.
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Three studies assessed this therapeutic strategy.47–49 Ramiro et 
al47 enrolled patients requiring any kind of oxygen support, 
reporting that the proportion of patients receiving IMV was 
higher in the cohort of patients treated with SOC versus those 
receiving TCZ (15% vs 1%). The treatment protocol included 
sequential MTP and TCZ, the latter added if lack or clinical 
response to MTP within 2–5 days. Historical control groups 
were identified among patients referred to the same centre 
in the previous month and receiving SOC only. Significant 
positive effects were observed in the TCZ+MTP group with 
regard to mortality, IMV, oxygen support, clinical improve-
ment and time to discharge. Of note, day-28 mortality rate in 
the control group was high (48%).
Likewise, Sanz Herrero et al49 compared patients receiving 
TCZ either monotherapy or in combination with MTP and 
reported that combination therapy was superior to mono-
therapy in reducing the risk of death. On the contrary, Gupta 
et al50 reported that the association between TCZ treatment 
and mortality was similar in patients having received or not 
glucocorticoids on ICU admission (HRs (95% CI) 0.68 (0.46 
to 0.99) and 0.71 (0.53 to 0.96)), respectively.
Safety
One study at unclear RoB reported that although the overall 
rate of adverse events was comparable in the treatment 
groups, there was a trend towards more pulmonary embolism 
in the TCZ+glucocorticoids group (p=0.059). Arrhythmias 




The combination of baricitinib and glucocorticoids added to 
SOC was assessed in a study at high RoB.51 Patients with severe 
COVID-19, half of which were receiving NIV (IMV was an 
exclusion criterion) received three consecutive days of pulse 
MTP therapy (80, 125 or 250 mg/day) followed by prednisone 
at a starting dose of 30 mg/day tapered until discontinuation 
within 7–10 days. Those receiving only MTP were compared 
with those receiving also baricitinib from day 3 (2 or 4 mg/day), 
and the combination therapy (regardless of the baricitinib dose) 
was linked to more pronounced clinical improvement, a lower 
use of supplemental oxygen both at discharge and 1 month later 
was compared with MTP+SOC.
Safety
A number of adverse events occurred in the two treatment 
groups, including infectious and cardiac adverse events, but the 
authors did not flag any specific scenario attributable to barici-
tinib. Of particular interest, occurrence of venous thromboem-
bolism, a class warning for JAK inhibitors, was similar in the two 
treatment groups.
Other immunomodulatory drugs
A few small prospective studies at variable RoB evaluated mavrili-
mumab,52 lenzilumab,53 eculizumab,54 sarilumab,55 recombinant 
human IL-756 and the combination of ruxolitinib+eculizumab,57 
ruxolitinib+glucocorticoids58 and cyclosporin+glucocorti-
coids.59 However, none of them provided solid positive results.
One retrospective controlled study of infliximab at high 
RoB showed comparable mortality rate and need of IMV in 17 
patients with COVID-19 treated with SOC versus seven patients 
receiving infliximab in addition to SOC. In the ‘grey literature’, 
we came across other ongoing studies with infliximab (ACTIV-1: 
NCT04593940 and CATALYST: ISRCTN40580903) and adali-
mumab (AVID- CC: ISRCTN33260034).60 One retrospective 
study explored anakinra in combination with glucocorticoids 
reporting a possible benefit in reducing mortality.61
Data from non-controlled studies
Canakinumab was evaluated in one retrospective non- controlled 
study and one case report,62 63 tesidolumab was assessed in one 
retrospective study64 and itolizumab was assessed in a prospec-
tive non- controlled study.65 These studies showed favourable, 
although very preliminary results, that required to be confirmed 
in controlled studies.
Table 4 ’Grey literature’ concerning randomised controlled trials
Drug Study name Author, year Study groups Efficacy Safety Risk of bias
Tocilizumab REMAP- CAP Gordon et al 2020 SOC*
SOC* +TCZ
SOC* +SARI
Compared with control, median adjusted ORs for 
hospital survival were 1.64 (95% CrI 1.14, 2.35) 
for TCZ and 2.01 (95% CrI 1.18 to 4.71) for SARI. 
TCZ and SARI were effective across all secondary 
outcomes, including 90- day survival, time to ICU 
and hospital discharge and improvement in the 
WHO ordinal scale at day 14.
Nine serious adverse events reported in the 
TCZ group including one secondary bacterial 
infection, five bleeds, two cardiac events and 
one deterioration in vision. Eleven serious 
adverse events in the control group, four 
bleeds and seven thromboses. No serious 
adverse events in the SARI group.
Unclear
TCZ COVACTA Rosas et al 2020 SOC† +PBO
SOC† +TCZ
No difference between groups in mortality at 
day 28 between TCZ (19.7%) and PBO (19.4%) 
(difference, 0.3% (95% CI −7.6 to 8.2); nominal 
p=0.94).
Post hoc analysis on patients not on IMV: Among 
patients not receiving MV at randomisation, less 
patients in the TCZ group experienced any clinical 
failure at day 28 compared with PBO (29% vs 
42.2%) HR 0.614; 95% CI 0.40 to 0.94; nominal 
p=0.03).
Serious adverse events occurred in 34.9% of 
295 patients in the TCZ arm and 38.5% of 143 
in the PBO arm.
Unclear
*Standard care of each recruiting site. Since participants could be randomised to other interventions within other domains, depending on domains active at the site, patient eligibility and consent 
(see www.remapcap.org). Randomisation to the corticosteroid domain for COVID-19 closed on 17 June 2020.12 Thereafter, corticosteroids were allowed as per recommended standard of care.
†Standard care per local practice (antiviral treatment, low- dose steroids, convalescent plasma and supportive care) was permitted; however, concomitant treatment with another investigational 
agent (except antivirals) or any immunomodulatory agent was prohibited.
AE, adverse event; AZT, azithromycin; COL, colchicine; CrI, credibility interval; DEX, dexamethasone; HCQ, hydroxychloroquine; HCT, hydrocortisone; ICU, intensive care unit; MTP, 
methylprednisolone; PBO, placebo; RUXO, ruxolitinib; SAE, severe adverse event; SARI, sarilumab; SE, standard error; SOC, standard of care; TCZ, tocilizumab.
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Table 5 Effect and safety of immunomodulatory drugs assessed in mild COVID-19 (without oxygen support)
Outcome Drug Author, year (ref) Study design Study groups Results Risk of bias
Mortality Hydroxychloroquine Lyngbakken et al 202078 RCT SOC+HCQ
SOC
No difference between groups. High
    Ulrich et al 202021 RCT SOC+HCQ
SOC
No difference between groups at day 14 for the composite 
criteria (death, ICU admission, mechanical ventilation, 
extracorporeal membrane oxygenation and/or vasopressor 
use).
High
  Baricitinib Bronte et al 202074 Prospective SOC+BARI
SOC
1/20 (5%) in BARI group versus 25/56 (45%) SOC group 
(p<0.001).
High
  IFN alpha Wang et al 202071 Prospective SOC+IFN alpha- 2b
SOC
None of the patients died in any group. High
Discharge/Time to 
Hospital Discharge
Hydroxychloroquine Lyngbakken et al 202078 RCT SOC+HCQ
SOC
No difference between groups p by log- rank test=0.71. High
  Baricitinib Cantini et al 202073 Prospective SOC+BARI
SOC
Discharge at week 2 occurred in 58% (7/12) of the BARI- 
treated patients versus 8% (1/12) of controls (p=0.027).
High
  Leflunomide Wang et al 202069 RCT SOC+LEF
SOC
No difference between groups 29.0 (IQR 19.3–47.3) days 
versu 33.0 (IQR 29.3–42.8) days p=0.170.
High
  IFN alpha Wang et al 202071 Prospective SOC+IFN alpha- 2b
SOC
Shorter time to discharge in the treatment group. Even 
shorter if early intervention.
High
Negative conversion of 
SARS- CoV-2
Hydroxychloroquine Mitja et al 202066 RCT SOC+HCQ SOC No difference across groups day 3 and day 7. Unclear
    Chen et al 202017 RCT SOC+HCQ SOC No difference in time to negative PCR at day 14: 5 days 
(95% CI 1 to 9 days) and 10 days (95% CI 2 to 12 days) for 
the HCQ and SOC groups, respectively (p=0.40).
High
    Omrani et al 202068 RCT SOC+HCQ SOC No difference across groups
day 6 negative PCR (p=0.821)
HCQ+AZT 16/152 (10.5%), HC 19/149 (12.8%), placebo 
18/147 (12.2%).
Day 14 (p=0.072) HC +AZ 30/149 (20.1%), HC 42/146 
(28.8%), placebo 45/143 (31.5%).
High
  Leflunomide Hu et al 202070 RCT SOC+LEF
SOC
5 days LEF versus 11 days control group (p=0.046). High
    Wang et al 202069 RCT SOC+LEF
SOC
No difference between groups
HR for negative RT- PCR, 0.70; (95% CI 0.391 to 1.256; 
p=0.186).
High
  IFN alpha Wang et al 202071 Prospective SOC+IFN alpha- 2b
SOC
Faster in the treatment group. High
  IFN kappa Fu et al 202072 RCT SOC+IFN kappa SOC Significantly shorter time to viral RNA negative conversion 
in IFN group.
Unclear
Treatment emergent AEs Hydroxychloroquine Mitjà et al 202066 RCT SOC+HCQ
SOC
AE in SOC 16/184 (8.7%)<121/169 (72.0%) in HCQ group. Unclear
    Skipper et al 202067 RCT SOC+HCQ
SOC
AEs with HCQ >PBO at day 5 (43% (92 of 212) versus 22% 
(46 of 211); p<0.001). GI symptoms in 31% (66 of 212).
Unclear
    Chen et al 202017 RCT SOC+HCQ
SOC
No SAE reported. Grades 1 and 2 HCQ- related adverse 
events included headache (21.1%), dizziness (5.3%), 
gastritis (5.3%), diarrhoea (5.3%), nausea (5.3%) and 
photophobia (5.3%).
High
    Omrani et al 202068 RCT SOC+HCQ
SOC
No SAE. No association (p=0.708) between study group 
and development of pneumonia, which was diagnosed 
in seven participants (1.5%): three (2.0%) in the HC+AZ 
group, one (0.7%) in the HC group and three (2.0%) in the 
placebo group.
High
    Ulrich et al 202021 RCT SOC+HCQ
SOC
No difference in AEs between the groups. HCQ was 
associated with a slight increase in mean corrected QT 
interval, an increased D- dimer and a trend towards an 
increased length of stay.
High
  Leflunomide Hu et al 202070 RCT SOC+LEF
SOC
ALT and AST reversibly increased LEF group (p=0.049 and 
p=0.176, respectively).
High
    Wang et al 202069 RCT SOC+LEF
SOC
No difference in AEs between the groups. High
  Tocilizumab Zhao et al 202075 RCT SOC+favipiravir
SOC+favipiravir +TCZ
Nine adverse reactions were reported in the combined 
treatment group, and two adverse reactions were reported 
in the favipiravir group and the TCZ group, respectively.
High
  Baricitinib Cantini et al 202073 Prospective SOC+BARI
SOC
No SAEs. 1 patient with transaminases elevation in the 
BARI group.
High
    Bronte et al 202074 Prospective SOC+BARI
SOC
No SAEs. High
  IFN alpha Wang et al 202071 Prospective SOC+IFN alpha- 2b
SOC
No difference in AEs between the groups. High
  IFN kappa Fu et al 202072 RCT SOC+IFN kappa SOC No SAEs. Unclear
Only studies reporting on the corresponding outcome are shown.
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AZT, azithromycin; BARI, baricitinib; COL, colchicine; DEX, dexamethasone; GI, gastrointestinal; HCQ, hydroxychloroquine; HCT, 
hydrocortisone; IFN, interferon; LEF, leflunomide; MTP, methylprednisolone; PBO, placebo; RT- PCR, real time PCR; RUXO, ruxolitinib; SAE, severe adverse event; SAEs, serious adverse events; SE, standard error; SOC, 
standard of care; TCZ, tocilizumab.
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Immunomodulatory therapies with evidence on mild 
COVID-19 (without oxygen therapy)
Six immunomodulatory strategies were assessed in RCTs at 




Five RCTs evaluated HCQ in mild to moderate COVID-
19,17 21 66–68 but none of them demonstrated any benefit with 
the addition of this drug to SOC (including in milder non- 
hospitalised patients.66 67
Safety
In line with what was reported from studies in severe COVID-
19, the RCTs enrolling mild to moderate COVID-19 highlighted 
safety concerns for HCQ since a higher number of adverse events 
were observed in the HCQ- SOC group compared with SOC.
Other immunomodulatory drugs
Two small RCTs at high RoB reported on leflunomide.69 70 One 
study observed no difference in length of hospital stay,69 while 
conflicting results were reported by both studies with regard to 
a possible effect on negative conversion of SARS- CoV-2. Safety 
concerns were raised by one of the studies with increased liver 
enzymes in leflunomide- treated patients.70
IFN- alpha71 and IFN- kappa72 reduced the time to negative 
conversion of SARS- CoV-2 in two studies. Two prospective 
studies on baricitinib at high RoB provided conflicting results 
for every assessed outcome and only agreed on the fact that addi-
tion of baricitinib to SOC did not worsen the safety profile of 
the therapeutic strategy.73 74 One small study evaluated TCZ+-
favipavir demonstrating positive effects on lung inflammation.75
DISCUSSION
Our SLR has shown that despite the large bulk of articles inves-
tigating several immunomodulatory drugs for the treatment of 
SARS- CoV-2 infection, most studies are at high or unclear RoB, 
and robust evidence on efficacy is available only for a few drugs 
and for a low number of outcomes. In particular, data from RCTs 
showed that the addition of HCQ to SOC was not beneficial at 
any stage of SARS- CoV-2 infection, while glucocorticoids may 
reduce mortality in some subgroups of patients with moderate, 
severe or critical COVID-19. The latter evidence is mainly 
driven by the large RECOVERY trial.6 Regarding TCZ, three 
available RCT were positive, but three other RCTs are negative. 
Thus, TCZ could have a place in some specific subgroups that 
remain to be determined.23 76
The SLR identified a number of pitfalls that prevented the 
comparison of retrieved studies and constrains results interpre-
tation. First, heterogeneity of inclusion criteria even in studies 
claiming to assess the same patient subgroup (eg, severe COVID-
19) was often observed. In fact, various parameters, such as the 
partial pressure of oxygen (PaO2)/fractional inspired oxygen 
ratio, C reactive protein level and peripheral oxygen saturation 
to cite a few, with different cut- off values, have been used to clas-
sify patients contributing to a relevant selection bias. We tried to 
overcome this issue and harmonise the presentation of results 
using a framework inspired by one the WHO scales.77
In RCTs, the definition of ‘standard of care’ was also highly 
variable making data interpretation difficult. Every immuno-
modulatory drug that has been assessed was added on top of 
SOC and compared (with a few exceptions) with SOC alone. 
However, in COVID-19, SOC changed rapidly, and the 
approaches recommended as SOC in March 2020 were not the 
same as in the subsequent months. Moreover, other factors such 
as local/national regulations or recommendations, criteria for 
hospital admission/IMV or differing drug availability increased 
study variability even if published within the same timeframe. 
In addition, in some studies, the treatment, including glucocorti-
coids, interferon or other immunomodulatory drugs, was left at 
the discretion of the treating physician, meaning that a subgroup 
of the intervention group could receive other drugs in a non- 
standardised manner, subsequently affecting the interpretability 
of the results.
In prospective observational studies, the main pitfall was that 
the control groups were often historical and thus not comparable 
with the studied group, even if adjusted for baseline character-
istics, given the rapid evolution in the treatment of the disease. 
Finally, yet importantly, study outcomes along with the timing of 
their assessment largely varied across studies.
In conclusion, this SLR informed the EULAR initiative to 
formulate PtC on COVID-19 pathophysiology and immuno-
modulatory therapies. However, the results of the present SLR 
also underscored the need of RCTs with standardised inclusion 
criteria and outcomes in order to robustly elucidate the effect 
of immunomodulatory drugs at different stages of SARS- CoV-2 
infection and ultimately improve the care and prognosis of 
affected people. Another important aspect to be further explored 
is the identification of factors predicting efficacy of the selected 
drug(s) in a specific population.
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